Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy

December 20, 2013

An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.

In this issue of the Journal of Clinical Investigation, Frédéric Batteux and colleagues at the Laboratoire d'Immunologie evaluated use of the MRI contrast agent mangafodipir, which has antioxidant properties, for relief of -associated neuropathies. In a mouse model of oxaliplatin-induced neurologic damage, administration of mangafodipir reduced neurotoxicity and the presence of oxidized protein products. Furthermore, in a cohort of 22 patients with oxaliplatin-associated neuropathy, mangafodipir treatment appeared to decrease .

In their accompanying commentary, Charles Loprinzi and colleagues at the May Clinic caution that even though these results seem promising, larger clinical trails have not been able to confirm similar results from other agents that have shown promise for treating chemotherapy-induced neuropathy in animal models and small phase II small.

Explore further: Research results in big savings for cancer treatment

More information: Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir, J Clin Invest. DOI: 10.1172/JCI68730
The search for treatments to reduce chemotherapy-induced peripheral neuropathy, J Clin Invest. 2014;124(1):72–74. DOI: 10.1172/JCI73908

Related Stories

Medication duloxetine helps reduce pain from chemotherapy

April 2, 2013

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...

Recommended for you

Raising the curtain on cerebral malaria's deadly agents

December 6, 2016

Using state-of-the-art brain imaging technology, scientists at the National Institutes of Health filmed what happens in the brains of mice that developed cerebral malaria (CM). The results, published in PLOS Pathogens, reveal ...

Re-emergence of syphilis traced to pandemic strain cluster

December 5, 2016

Over the last few decades, an age-old infectious disease has been re-emerging globally: syphilis. Using techniques to analyze low levels of DNA, an international research team headed by the University of Zurich has now shown ...

New mechanism to control human viral infections discovered

December 5, 2016

A team of researchers, co-led by a University of California, Riverside professor, has found a long-sought-after mechanism in human cells that creates immunity to influenza A virus, which causes annual seasonal epidemics and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.